ArticleMultimedia tools and applications2023
Recent developments on computer aided systems for diagnosis of diabetic retinopathy: a review.
Article in Multimedia tools and applications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 23 citations in OpenAlex.
- A hybrid CNN-GNN and multitask learning pipeline for improving mild diabetic retinopathy sensitivity.MethodsX · 2026Article
- FISM: harnessing deep learning and reinforcement learning for precision detection of microaneurysms and retinal exudates for early diabetic retinopathy diagnosis.BioData mining · 2025Article
- ODDM: Integration of SMOTE Tomek with Deep Learning on Imbalanced Color Fundus Images for Classification of Several Ocular Diseases.Journal of imaging · 2025Article
- Implementing and evaluating a fully functional AI-enabled model for chronic eye disease screening in a real clinical environment.BMC ophthalmology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is a long-term condition in which the pancreas quits producing insulin or the body's insulin isn't utilised properly. One of the signs of diabetes is Diabetic Retinopathy. Diabetic retinopathy is the most prevalent type of diabetes, if remains unaddressed, diabetic retinopathy can affect all diabetics and become very serious, raising the chances of blindness. It is a chronic systemic condition that affects up to 80% of patients for more than ten years. Many researchers believe that if diabetes individuals are diagnosed early enough, they can be rescued from the condition in 90% of cases. Diabetes damages the capillaries, which are microscopic blood vessels in the retina. On images, blood vessel damage is usually noticeable. Therefore, in this study, several traditional, as well as deep learning-based approaches, are reviewed for the classification and detection of this particular diabetic-based eye disease known as diabetic retinopathy, and also the advantage of one approach over the other is also described. Along with the approaches, the dataset and the evaluation metrics useful for DR detection and classification are also discussed. The main finding of this study is to aware researchers about the different challenges occurs while detecting diabetic retinopathy using computer vision, deep learning techniques. Therefore, a purpose of this review paper is to sum up all the major aspects while detecting DR like lesion identification, classification and segmentation, security attacks on the deep learning models, proper categorization of datasets and evaluation metrics. As deep learning models are quite expensive and more prone to security attacks thus, in future it is advisable to develop a refined, reliable and robust model which overcomes all these aspects which are commonly found while designing deep learning models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.